Cogent Biosciences (COGT) has drawn fresh attention after announcing that pivotal APEX trial data for bezuclastinib in Advanced Systemic Mastocytosis will be presented at the European Hematology Association 2026 Congress.

The announcement of new APEX and JAK2 data comes after a strong run in total shareholder return, with a very large 1 year gain and multi year returns above 200%, even as the 1 month share price return is down 6.3% and short term moves remain choppy around the latest close of US$34.19.

If this kind of biotech catalyst has your attention, it could be a good moment to scan for other healthcare stocks using AI as a growth lever through our 34 healthcare AI stocks

After such a sharp multi year run, a recent pullback, a growing clinical pipeline and an analyst price target that sits well above the latest close, should you view Cogent as undervalued today or assume the market is already pricing in future growth?

Price To Book Of 10.8x: Is It Justified?

Cogent is currently valued at a P/B of 10.8x, which sits well above both its biotech peers and the broader US Biotechs industry, even after the recent pullback to $34.19.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. For a clinical stage biotech that is still reporting losses and has no meaningful revenue, a high P/B often reflects how much investors are willing to pay today for the potential of the pipeline rather than current fundamentals.

In Cogent’s case, that pipeline focus comes with trade offs. The company is currently unprofitable, reports a loss of $354.303m, and has a negative return on equity of 58.3%. At the same time, the market is assigning a valuation that is expensive versus both the US Biotechs industry average P/B of 2.4x and the peer group average of 8.3x, and there is no SWS DCF fair value to cross check this pricing against.

With no meaningful revenue reported, no DCF anchor and an above average P/B, the current valuation leans heavily on expectations for future success in the clinical pipeline rather than on present financial performance.

Result: Price to book of 10.8x (OVERVALUED)

However, the story can change quickly if key trials disappoint or if sentiment cools on high multiple biotechs that are still reporting sizeable losses.

Next Steps

If the mix of enthusiasm and caution in this story feels familiar, it is worth checking the numbers yourself and weighing both sides of the debate. To see how the potential upside compares with the concerns flagged by other investors, review the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Cogent has sparked fresh questions about where to put capital next, do not stop here. Use structured stock lists to spot other opportunities before they move.

• Target resilient balance sheets and steady fundamentals with the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for quality at a discount by scanning the 47 high quality undervalued stocks.
• Unearth potential future standouts that many investors may be overlooking through the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.